The genus Citrobacter was designated in 1932 and included seven species: Citrobacter freundii (type strain), C. diversum, and five others (6) . Over time, only C. freundii and C. diversum (later described as C. diversus [2] ) remained as valid names. C. amalonaticus and C. amalonaticus biogroup 1 (3) completed the four groups that have been recognized for the past several years.
In 1990, Frederiksen (4) pointed out a potential error that had occurred in 1972 when C. diversus was published. He requested that the incorrect name C. diversus be rejected and replaced by C. koseri. At that time, three valid names, C. diversus, C. koseri, and Levinea malonatica, were apparently the same taxon. His request was later granted by the Judicial Commission of the International Committee on Systematic Bacteriology (5) . The Centers for Disease Control and Prevention has adopted the decision of the commission and will use the recognized name C. koseri.
Microbiologists around the world recognized that many strains of Citrobacter isolated from humans were difficult to characterize and classify into the three recognized species. Reference laboratories maintained stock strains of atypical Citrobacter spp. Recently, Brenner et al. (1) responded to the historical issue of problems within the Citrobacter group and examined 112 typical and atypical strains by DNA relatedness studies (hydroxyapatite method). Their work resulted in the recognition of 11 Citrobacter species, including five newly named species and three unnamed genomospecies, in addition to C. freundii (type species), C. koseri, and C. amalonaticus.
Identifying 11 species and groups of Citrobacter in the clinical laboratory could pose a problem, especially since the manufacturers of identification systems have not yet had time to respond. Clearly, the new names are not included in existing databases. In addition, reference laboratories that use conventional biochemical testing may have difficulty separating the new strains. Our laboratory examined the potential ability of some commercial identification systems to separate these Citrobacter species with the existing configuration of the system that generates a biocode for each isolate. We also present a simplified dichotomous key designed to assist in the recognition of all 11 species of Citrobacter.
Organisms. The 112 strains described by Brenner et al.
(1) were removed from storage at Ϫ70ЊC and passed twice on 5% sheep blood agar (Becton Dickinson Microbiology Systems, Cockeysville, Md.) prior to inoculation into commercial identification systems. When the isolate was to be inoculated into the MicroSCAN Walk/Away panels, it was passed once onto MacConkey's agar (Becton Dickinson Microbiology Systems). Although more organisms for testing would strengthen the evaluation reported here, the availability of hybridized strains with genetically confirmed identifications is limited.
Commercial identification systems. The Vitek system (bioMérieux Vitek, Hazelwood, Mo.) was used with the GNI card and version R08.1 software. The MicroSCAN Walk/Away (Baxter Diagnostics, Inc., West Sacramento, Calif.) was used with the Rapid Neg Combo 3 panel and version 19.11 software. The Biolog MicroStation System (Biolog, Inc., Hayward, Calif.) was used with the Biolog GN Microplate and version 3.0 software. The RapID onE system (Innovative Diagnostic Systems, Inc., Norcross, Ga.) used Version onE V1.93 Code Compendium. The API 20E (bioMérieux Vitek, Hazelwood, Mo.) was used with its current Profile Index. Profile numbers not in the index were entered into the telephone computer database. Each product was used according to each manufacturer's directions.
Identification key. The biochemical data for the dichotomous key ( Fig. 1) were derived from Table 1 . Where possible, only those reactions exhibiting a 100 or 0% response were used. Because of the limited number of biochemicals incorporated and because some species demonstrate variable reactions, this dichotomous key is not intended to be used for reference identification but rather as a method for determining a presumptive identification with conventional biochemicals to be confirmed by more-extensive testing.
The commercial systems used in this study were evaluated for their ability to accurately identify C. freundii, C. diversus, C. amalonaticus, and C. amalonaticus biogroup 1, using the database profiles currently published (the old nomenclature). Table 2 also presents the results a laboratory might expect when the newly recognized species and groups of Citrobacter are inoculated into these five systems with their current databases which only contain the species C. freundii, C. diversus, and C. amalonaticus. Only the RapID onE was able to identify all nine strains of C. freundii accurately. The 16 C. diversus strains were renamed C. koseri. The RapID onE, Vitek, and Walk/Away were able to identify them all; Biolog C. werkmanii
C. freundii
Ն99.3%
C. sedlakii
C. amalonaticus The five new species and three new genomospecies of Citrobacter were all previously called C. freundii. In the Vitek, 11 of the C. youngae strains were identified as C. freundii, but 9 were identified as E. coli. Of these nine, eight were identified at probabilities of Ͼ98%. All of the C. sedlakii and group 9 strains tested were identified as Enterobacter amnigenus biogroup 2. The Walk/Away identified four of six C. sedlakii strains as E. coli. In the RapID onE, the group 9 strains were assigned ''no code.'' Table 2 summarizes all identifications for all five systems when tested with the newly named strains.
For reference laboratories, and for those that prefer conventional biochemical methods as backup identification procedures, a flowchart was developed to facilitate recognition of the new genomospecies (Fig. 1) . Because some of the reactions used in the diagram do not represent 0% or 100% responses of the organisms, and because few organisms have been evaluated with it, the chart must be used only as a presumptive method of identification to be confirmed by more-extensive testing if deemed necessary.
We believe that the manufacturers of the systems used in this study will be able to incorporate selected strains of the new Citrobacter genomospecies with only minor adjustments in their current algorithms. As more data on these species appear in the literature, a clearer picture of their clinical significance should emerge.
